Contact
Login
Forgot password?
Prism_2_LOGO_png.png
About PRISM 2
Facts & Figures
Expected Impact
Management
Partners
Advisory Boards
For Scientists
Background
Objectives
Work Packages
Publications
For Patients & Relatives
Clinical Study
Public Deliverables
Useful Links
Downloads
News & Events
Project News & Events
Project Meetings
Press Coverage
Scientific Conferences

PRISM    

Contact
Login

PRISM 2 project
Precision medicine for psychiatry:
From brain function to behaviour

About PRISM 2

Our Vision

Currently, neuropsychiatric disorders are largely diagnosed and treated with symptom-based approaches, lacking reference to quantitative biological underpinnings. This weakness impedes both innovative drug development and effective treatment. The preceding PRISM project has successfully identified quantitative neurobiological parameters related to Schizophrenia (SZ), Alzheimer’s Disease (AD), and to social function irrespective of diagnosis. PRISM 2 builds on PRISM outcomes and has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between default mode network (DMN) integrity and social dysfunction in SZ and AD and determine its potential to generalise to Major Depressive Disorder (MDD). Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. And third, to implement project results to the benefit of patients and health care providers. Our vision is that in the future every psychiatric patient receives the most accurate diagnosis and best possible treatment based on precise quantitative technologies and a deeper biological understanding of these brain disorders.

Read more
Clinical Study

In the Patient's Brain

Certain behavioural phenomena, such as social dysfunction, are common across various psychiatric and neurological disorders. Social withdrawal from established social networks, colleagues, or friends, for example, is one of the earliest symptoms seen in patients with Alzheimer’s Disease (AD), Schizophrenia (SZ), or Major Depressive Disorder (MDD), and appears to be an early indicator of cognitive deficits. In the clinical study of the PRISM 2 project, patients will be recruited and assessed on two separate days, including screening and clinical interviews, completion of questionnaires, blood sampling, use of a new smartphone app (a product of the PRISM project), as well as electroencephalogram (EEG) and functional magnetic resonance imaging (fMRI) procedures. With these measurements, we aim to better understand the biological reasons for these severely impairing neuro-psychiatric diseases, improve diagnosis, and accelerate the development of new treatments. In total, we hope to recruit about 160 study participants. With these efforts, the PRISM 2 consortium is determined to exert a positive impact on public mental health and well-being.

Read more

Twitter

Tweets by IMI2PRISM2

Resources

  • Clinical Study
  • Work Packages
  • Publications
  • Partners
  • Useful Links
  • Downloads
  • Newsletter
  • Contact

Events

01-02 November 2023

6th SC meeting

Mainz, Germany
The sixth PRISM² SC meeting will be held from 01 – 02 November 2023.

Read more
See all news and events
Follow us on social media:
LinkedIn Twitter

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union’s Horizon 2020 research and innovation programme, EFPIA, and Cohen Veterans Bioscience (CVB). The website reflects only the authors' views and IMI JU, EFPIA, CVB, and the European Commission are not responsible for any use that may be made of the information it contains.

Login Contact Privacy Policy Legal Disclaimer
© PRISM 2 consortium 2023
Manage Cookie Consent
We use cookies to improve your experience. Until you consent, only those cookies necessary to maintain the website's basic functionality are active. Website features, security and statistics are best if you activate "All cookies" (incl. Twitter, YouTube, Google reCAPTCHA and Google Analytics). You can revoke your choice at any time. Just clear your browser cache and update your settings. Please also view our Privacy Policy.

 
Functional cookies only Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistical cookies
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
All cookies
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Your cookie preferences
{title} {title} {title}